1. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends Immunother 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20

2. Furukawa F. The Nobel Prize in physiology or medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends Immunother 2018; 2(3). doi:10.24294/ti.v2.i3.1065

3. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90(2): 720-724. doi:10.1073/pnas.90.2.720

4. Kuwana Y, Asakura Y, Utsunomiya N et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1993; 149(3): 960-968. doi:10.1016/0006-291x(87)90502-x

5. Maher J, Brentjens RJ, Gunset G et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20 (1): 70-75. doi:10.1038/nbt0102-70

6. Marvin de los Santos, Samuel D. Bernal. CAR-T therapy for solid tumors: development of new strategies. Trends Immunother 2018; 2(3). doi:10.24294/ti.v2i3.1064

7. Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019; 11(482). pii:eaav1648. doi:10.1126/scitranslmed.aav1648